SAN DIEGO – (BUSINESS WIRE) –Artiva Biotherapeutics, Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells optimized for their ability to kill tumors, today announced the closing of a Series B funding of $ 120 million. New investor Venrock Healthcare Capital Partners led the funding. Other new investors participating in the funding included Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, LP, Surveyor Capital (a Citadel company), Wellington Management Company and a leader not disclosed …
Read Additional From Source
Copyright @ www.businesswire.com
News Highlights Finance
- Headline: Artiva Biotherapeutics Raises $ 120 Million in Series B Funding to Advance Its NK Allogeneic Cell Therapies Pipeline
- Check all news and articles from the Finance news updates.